Regulatory fallout from a scandal surrounding the fabrication of data used to support a molecular test in a Duke University cancer trial is exacting an unjustifiable toll not only on health economics but also on patient lives.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hart, P.K. Houston docs found leak in Holy Grail of cancer treatment. Houston Chronicle http://www.chron.com/news/kilday-hart/article/Hart-Houston-docs-found-leak-in-Holy-Grail-of-3341794.php (18 February 2012).
Institute of Medicine. Evolution of translational omics: lessons learned and the path forward. http://www.iom.edu/Reports/2012/Evolution-of-Translational-Omics/Report-Brief.aspx (23 March 2012).
US Food and Drug Administration. Device advice: investigational device exemption (IDE). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance /HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/default.htm (updated 23 December 2013).
Kim, E.S. et al. Cancer Discov. 1, 44–53 (2011).
Beckloff Associates, Inc. The regulatory paradox of laboratory developed tests. http://cardinalhealth.com/beckloff/documents/pdf/TheRegulatoryParadoxofLaboratoryDevelopedTests.pdf (accessed 12 December 2013).
Non-Small Cell Lung Cancer Collaborative Group. Br. Med. J. 311, 899–909 (1995).
National Cancer Institute. Non-small cell lung cancer treatment. http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/page11#Section_48414 (updated 30 May 2013).
Laack, E. et al. J. Clin. Oncol. 22, 2348–2356 (2004).
Monnerat, C. & Le Chevalier, T. Ann. Oncol. 17 (suppl. 5), v86–v90 (2006).
Spigel, D.R. et al. J. Thorac. Oncol. 5, 841–845 (2010).
D'Addario, G. et al. J. Clin. Oncol. 23, 2926–2936 (2005).
Rajeswaran, A., Trojan, A., Burnand, B. & Giannelli, M. Lung Cancer 59, 1–11 (2008).
Pujol, J.L., Barlesi, F. & Daurès, J.P. Lung Cancer 51, 335–345 (2006).
Verma, S. et al. N. Engl. J. Med. 367, 1783–1791 (2012).
US Food & Drug Administration. FDA approves new treatment for late-stage breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm (22 February 2013).
Burris, H.A. III et al. J. Clin. Oncol. 29, 398–405 (2011).
F. Hoffman-La Roche Ltd. Roche provides update on FDA application for T-DM1. http://www.roche.com/media/media_releases/med-cor-2010-08-27.htm (27 August 2010).
Stewart, D.J., Whitney, S.N. & Kurzrock, R. J. Clin. Oncol. 28, 2925–2935 (2010).
Westin, J.R. & Kurzrock, R. Mol. Cancer Ther. 11, 2549–2555 (2012).
Kantarjian, H. et al. N. Engl. J. Med. 362, 2260–2270 (2010).
Behazin, N.S. Gastrointestinal stromal tumors. Medscape http://emedicine.medscape.com/article/179669-overview (updated 11 March 2013).
Stewart, D.J. & Kurzrock, R. J. Clin. Oncol. 27, 328–333 (2009).
Schulman, K.A. J. Investig. Med. 58, 31–32 (2010).
Most clinical trials done abroad. Wall Street Journal http://online.wsj.com/news/articles/SB123499424805316443 (18 February 2009).
Janku, F. et al. Clin. Cancer Res. 18, 6356–6363 (2012).
Tsimberidou, A.M. et al. Clin. Cancer Res. 18, 6373–6383 (2012).
Stewart, D.J. & Kurzrock, R. BMC Cancer 13, 193 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.K. received a Merck Honorarium ($3,500). D.J.S. has been a consultant for various firms, including the Frankel Group, Aligh2Action, Amgen, Roche Canada, Boehringer Ingelheim Canada and Guidepoint Global; has been a speaker at events sponsored by Pfizer Canada, AstraZeneca Taiwan and Ventana; and has been supported by grants to his institution from AstraZeneca, Roche Canada and Pfizer. None of foregoing for D.J.S. is related to the present work.
Rights and permissions
About this article
Cite this article
Kurzrock, R., Kantarjian, H. & Stewart, D. A cancer trial scandal and its regulatory backlash. Nat Biotechnol 32, 27–31 (2014). https://doi.org/10.1038/nbt.2792
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2792
This article is cited by
-
New drug approvals in oncology
Nature Reviews Clinical Oncology (2020)